Abstract
This study determined the flare status of SLE patients in a single-center Chinese cohort and identified the predictors of flare in this underreported Asian population. The patients were recruited from April 2009 to February 2010 at the Peking Union Medical College Hospital (PUMCH), and then followed up regularly at our clinic until December 2015. Flare was defined as an increase in SLEDAI-2K to ≥ 4 points from the previous visit, or appearing of a new SLE manifestation or worsening of a preexisting clinical or hematological manifestation (not included in SLEDAI-2K) that results in restarting or increasing corticosteroids or immunosuppressant. Baseline and follow-up data were collected, and some of them were used as variables in survival analysis for time-to-flare outcome with Kaplan-Meier survival analysis and log-rank tests. Potential predictors with significant differences were further included in a multivariate Cox regression model for confounders adjustment and hazard ratio (HR) calculation. A total of 254 patients were finally included in our analysis. Yearly flare proportion rate was 13.0–15.7%. Renal, hematologic, and neurologic were the most frequently involved organs. Multivariate analysis confirmed onset age up to 18 years (HR 2.14, 95% CI 1.09–4.19) as a flare predictor. Organ damage at entry also showed an association trend with flare (HR = 1.693, 95% CI 0.943 ~ 3.041, p = 0.078). Chinese SLE patients showed a higher prevalence for disease flare compared with other ethnics. Future studies should be designed for figuring out the prediction role of fluctuation of anti-dsDNA antibody for disease flare.
Similar content being viewed by others
References
Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, Grassi S, Alpigiani MG, Barbano G, Janz-Junior LL, Martini A, Ravelli A (2006) Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 15(8):515–520. https://doi.org/10.1191/0961203306lu2316oa
Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA, Truglia S, Miranda F, Spinelli FR, Alessandri C, Valesini G (2016) The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus 25(7):719–726. https://doi.org/10.1177/0961203315627199
Ugarte-Gil MF, Acevedo-Vasquez E, Alarcon GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, Segami MI, Wojdyla D, Soriano ER, Drenkard C, Brenol JC, de Oliveira E Silva Montandon AC, Costallat LT, Massardo L, Molina-Restrepo JF, Guibert-Toledano M, Silveira LH, Amigo MC, Barile-Fabris LA, Chacon-Diaz R, Esteva-Spinetti MH, Pons-Estel GJ, McGwin G Jr, Pons-Estel BA (2015) The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis 74(6):1019–1023. https://doi.org/10.1136/annrheumdis-2013-204620
Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, Zampieri S, Della Libera S, Perini G, Todesco S (2004) Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 43(12):1580–1586. https://doi.org/10.1093/rheumatology/keh392
Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, Guillemin F, Kobelt G, Maurel F, Garofano A, Perna A, Murray M, Schmitt C, Boucot I (2014) Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 73(1):154–160. https://doi.org/10.1136/annrheumdis-2012-202443
Doria A, Iaccarino L, La Montagna G, Mathieu A, Piga M, Galeazzi M, Iuliano A, Maurel FB, Garofano AM, Perna AG, Porcasi RE (2015) Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. Clin Exp Rheumatol 33(3):375–384
Lee J, Dhillon N, Pope J (2013) All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford) 52(5):905–909. https://doi.org/10.1093/rheumatology/kes391
Conti F, Ceccarelli F, Perricone C, Miranda F, Truglia S, Massaro L, Pacucci VA, Conti V, Bartosiewicz I, Spinelli FR, Alessandri C, Valesini G (2012) Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One 7(9):e45934. https://doi.org/10.1371/journal.pone.0045934
Floris A, Piga M, Cauli A, Mathieu A (2016) Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev 15(7):656–663. https://doi.org/10.1016/j.autrev.2016.02.019
Ines L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JA (2014) Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatology (Oxford) 53(1):85–89. https://doi.org/10.1093/rheumatology/ket322
Laustrup H, Voss A, Green A, Junker P (2010) SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus 19(3):239–246. https://doi.org/10.1177/0961203309351033
Nikpour M, Urowitz MB, Ibanez D, Gladman DD (2009) Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 61(9):1152–1158. https://doi.org/10.1002/art.24741
Steiman AJ, Gladman DD, Ibanez D, Urowitz MB (2012) Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res 64(4):511–518. https://doi.org/10.1002/acr.21568
Conti F, Ceccarelli F, Perricone C, Massaro L, Spinelli FR, Valesini G (2010) Low incidence of flare and persistent active disease in a cohort of Italian patients with systemic lupus erythematosus: comment on the article by Nikpour et al. Arthritis Care Res 62(6):899–900; author reply 900. https://doi.org/10.1002/acr.20145
Li M, Zhang W, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Zhang F, Zhao Y, Zeng X (2013) Chinese SLE treatment and research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus 22(11):1192–1199. https://doi.org/10.1177/0961203313499086
Cervera R, Doria A, Amoura Z, Khamashta M, Schneider M, Guillemin F, Maurel F, Garofano A, Roset M, Perna A, Murray M, Schmitt C, Boucot I (2014) Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev 13(6):621–629. https://doi.org/10.1016/j.autrev.2013.11.007
Mirzayan MJ, Schmidt RE, Witte T (2000) Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 39(12):1316–1319
Petri M, Genovese M, Engle E, Hochberg M (1991) Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 34(8):937–944
Petri M, Singh S, Tesfasyone H, Malik A (2009) Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 36(11):2476–2480. https://doi.org/10.3899/jrheum.090019
van den Berg L, Nossent H, Rekvig O (2006) Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol 25(3):347–352. https://doi.org/10.1007/s10067-005-0047-7
Ibanez D, Gladman DD, Urowitz MB (2005) Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 32(5):824–827
Wu CY, Li CF, Wu QJ, Xu JH, Jiang LD, Gong L, Wu FQ, Gu JR, Zhao JL, Li MT, Zhao Y, Zeng XF (2017) Chinese systemic lupus erythematosus treatment and research group registry IX: clinical features and survival of childhood-onset systemic lupus erythematosus in China. Chin Med J 130(11):1276–1282. https://doi.org/10.4103/0366-6999.206346
Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58(2):556–562. https://doi.org/10.1002/art.23204
Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, Dehoorne J, Joos R, Hendrickx G, Houssiau F, Elewaut D (2009) Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 68(3):412–415. https://doi.org/10.1136/ard.2008.094813
Livingston B, Bonner A, Pope J (2011) Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 20(13):1345–1355. https://doi.org/10.1177/0961203311416694
Funding
This study was supported by the Chinese National Key Technology R&D Program, Ministry of Science and Technology (2017YFC0907601, 2017YFC0907602, 2017YFC0907603 2008BAI59B02), the Chinese National High Technology Research and Development Program, Ministry of Science and Technology (2012AA02A513).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
This study was approved by the Ethics Committee of PUMCH, Chinese Academy of Medical Sciences (Approval number, S-197), and an informed consent form was obtained from all participants at the inclusion of new participants.
Disclosures
None.
Rights and permissions
About this article
Cite this article
Peng, L., Wang, Z., Li, M. et al. Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study. Clin Rheumatol 36, 2727–2732 (2017). https://doi.org/10.1007/s10067-017-3842-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3842-z